The short version of DAC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Chief Executive Officer, Key Assets Europe. For services to Fostering. Rowan Edwin Crozier. Chief Executive Officer, C Brandauer & Co. For services to Manufacturing and Enterprise. Dr. Donald Murray Cruickshank. General Practitioner, Upper Deeside. For services to the Medical Profession and to the community of Braemar, Aberdeenshire. Diana Jane Andrews Cunningham. Peer Trainer, Sussex Recovery College. For services to Mental Health. Suzette Louise Davenport, QPM. Chair, National Driver Offending Retraining Scheme. For services to Road Safety. Jessica Miriam Bryson Davidson. Senior Clinical Forensic Charge Nurse. For services to Forensic Nursing and to Victim Support in Scotland. Donna Marie Dawber. News and Campaigns Manager, Merseyside Police. For services to Law and Order. Dr. Edward James Day. Clinical Reader in Addiction Psychiatry, University of Birmingham. For services to Vulnerable People. Shaun Andrew Day. Headteacher, The Unicorn School, Abingdon, Oxfordshire. For services to Education. Paula Rosemary Deas. Deputy Chief Executive, Coventry and Warwickshire Local Enterprise Partnership. For services to the community in the West Midlands. Keith Deller. For charitable services to the community in Suffolk. Jack Robert Clarke Deverson. Co-Founder and Managing Director, Evidence Based Education. For services to Education. Ruth Heather Devine. Route Panel Member, Institute for Apprenticeships and Technical Education. For services to Further Education and Apprenticeships. Deborah Heather Dixon (Deborah Williams). For services to the community in Poole, Dorset.
== Preparation and composition == Some Native Americans used mashed pumpkin or devil's club as a poultice. In addition to bread and cereals, bran may also be used as a poultice because of its absorbent quality. It is packed into the wound and then covered with a piece of sacking or similar material before being bandaged onto the site of the wound. There are also many commercial poultices that are ready-made. Some of these may be labeled as "drawing salves". Ash poultices can cause a chemical burn.
When a polymer is dispersed or dissolved in a liquid, such as in commercial products like paints and glues, the chemical properties and molecular interactions influence how the solution flows and can even lead to self-assembly of the polymer into complex structures. When a polymer is applied as a coating, the chemical properties will influence the adhesion of the coating and how it interacts with external materials, such as superhydrophobic polymer coatings leading to water resistance. Overall the chemical properties of a polymer are important elements for designing new polymeric material products.
Sources: en.wikipedia.org
==== Firearms and criminal justice ==== In 1993, Sanders voted against the Brady Bill, which mandated federal background checks when buying guns and imposed a waiting period on firearm purchasers in the United States; the bill passed by a vote of 238–187. He voted against the bill four more times in the 1990s, explaining that his Vermont constituents saw waiting-period mandates as more appropriately a state rather than a federal matter. Sanders did vote for other gun-control measures. For example, in 1994, he voted for the Violent Crime Control and Law Enforcement Act "because it included the Violence Against Women Act and the ban on certain assault weapons." He was nevertheless critical of the other parts of the bill. Although he acknowledged that "clearly, there are some people in our society who are horribly violent, who are deeply sick and sociopathic, and clearly these people must be put behind bars in order to protect society from them", he maintained that governmental policies played a large part in "dooming tens of millions of young people to a future of bitterness, misery, hopelessness, drugs, crime, and violence" and argued that the repressive policies introduced by the bill were not addressing the causes of violence, saying, "we can create meaningful jobs, rebuilding our society, or we can build more jails." Sanders has at times favored stronger law enforcement and sentencing. In 1996, he voted against a bill that would have prohibited police from purchasing tanks and armored carriers.
=== Irregular and uneven bands === It has been claimed that a variety of odd and unequal bands, including black dots, white spots or bands, and curving bands, have occurred. The block dots are removed from the blots by effective blocking. White patches develop as a result of bubbles between the membrane and gel. White bands appear in the blots when main and secondary antibodies are present in significant concentrations. Because of the high voltage used during the gel run and the rapid protein migration, smiley bands appear in the blots. The strange bands in the blot are resolved by resolving these problems.
=== Special Counsel to Buddy Roemer === In 1988, Kennedy became special counsel to Governor Buddy Roemer. In 1991, he was also appointed secretary to the governor's cabinet and served in both posts until 1992. Roemer tasked Kennedy with helping him pass two key priorities: tort and campaign finance reforms. Roemer instructed Kennedy to draft the Louisiana Products Liability Act, a bill that aimed to set forth four clear legal theories by which manufacturers could be held liable for damage their products caused. The new code also clarified what counted as "unreasonably dangerous" to help make potential sources of liability more predictable to both businesses and buyers with claims. Roemer then tasked Kennedy with building support for passing the legislation. As part of his advocacy, Kennedy published a law review article titled "A Primer on the Louisiana Products Liability Act". He argued that the Products Liability Act would "bring added clarity, precision and certainty to Louisiana's products liability doctrine" and "strike an equitable balance between the right of a claimant who is injured in a product-related accident to just compensation and the right of the product's manufacturer to be judged fairly." Kennedy also delivered public testimony before the Louisiana House Committee on Civil Law and Procedure in support of the bill, saying that the bill "provides for a state-of-the-art defense for manufacturers." The Louisiana legislature enacted the Louisiana Products Liability Act in 1988.
A member of the People's Assembly (Arabic: عضو مجلس الشعب) refers to members of the Parliament of Syria. Historically, members of the Syrian parliament have been referred to in Arabic as nā'ib (نائب, "deputy"), plural nuwāb (نواب), a usage rooted in the legislature's earlier incarnation as the Chamber of Deputies (1932–1963). Following the parliament's reconstitution as the People's Assembly under Ba'athist rule in 1971, members came to be more commonly styled "member of the People's Assembly" in official and state-media usage. Nonetheless, "deputy" has persisted as a recognised designation, including in coverage of the current transitional-era Assembly formed after 2024.
Sources: en.wikipedia.org
==== Toxicity ==== Cardiac troponin T and I can be used to monitor drug and toxin-induced cardiomyocyte toxicity. . Chemotherapy agents can exert toxic effects on the heart (examples include anthracycline, cyclophosphamide, 5-fluorouracil, and cisplatin). Several toxins and venoms can also lead to heart muscle injury (scorpion venom, snake venom, and venom from jellyfish and centipedes). Carbon monoxide poisoning or cyanide poisoning can also be accompanied by the release of troponins due to hypoxic cardiotoxic effects. Cardiac injury occurs in about one-third of severe CO poisoning cases, and troponin screening is appropriate in these patients.
=== Identification of de novo emerging sequences === There are two major approaches to the systematic identification of novel genes: genomic phylostratigraphy and synteny-based methods. Both approaches are widely used, individually or in a complementary fashion. To standardise terminology for translated non-canonical ORFs (often implicated in de novo gene studies), a community proposal introduced the term "translons" to denote all translated regions detected by approaches such as ribosome profiling.
==== Therapy ==== Breast augmentation via autologous fat grafts allows the oncological breast surgeon to consider conservative breast surgery procedures that usually are precluded by the presence of alloplastic breast implants, e.g. lumpectomy, if cancer is detected in an implant-augmented breast. In previously augmented patients, aesthetic outcomes cannot be ensured without removing the implant and performing mastectomy. Moreover, radiotherapy treatment is critical to reducing cancerous recurrence and to the maximal conservation of breast tissue; yet, radiotherapy of an implant-augmented breast much increases the incidence of medical complications – capsular contracture, infection, extrusion, and poor cosmetic outcome.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.